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KIR haplotypes are associated with late-onset type 1 diabetes
in European–American families
JA Traherne1,2,6, W Jiang2,6, AM Valdes3, JA Hollenbach4, J Jayaraman2, JA Lane5, C Johnson2, J Trowsdale1,2 and JA Noble5
Classical human leukocyte antigens (HLA) genes confer the strongest, but not the only, genetic susceptibility to type 1 diabetes.
Killer cell immunoglobulin-like receptors (KIR), on natural killer (NK) cells, bind ligands including class I HLA. We examined presence
or absence, with copy number, of KIR loci in 1698 individuals, from 339 multiplex type 1 diabetes families, from the Human
Biological Data Interchange, previously genotyped for HLA. Combining family data with KIR copy number information allowed
assignment of haplotypes using identity by descent. This is the ﬁrst disease study to use KIR copy number typing and
unambiguously deﬁne haplotypes by gene transmission. KIR A1 haplotypes were positively associated with T1D in the subset of
patients without the high T1D risk HLA genotype, DR3/DR4 (odds ratio = 1.29, P= 0.0096). The data point to a role for KIR in type 1
diabetes risk in late-onset patients. In the top quartile (age of onset414), KIR A2 haplotype was overtransmitted (63.4%, odds
ratio = 1.73, P= 0.024) and KIR B haplotypes were undertransmitted (41.1%, odds ratio = 0.70, P= 0.0052) to patients. The data
suggest that inhibitory ‘A’ haplotypes are predisposing and stimulatory ‘B’ haplotypes confer protection in both DR3/DR4-negative
and late-onset patient groups.
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INTRODUCTION
Type 1 diabetes is an autoimmune disorder in which the insulin-
producing cells of the pancreas are destroyed, resulting in a
requirement for exogenous insulin for survival. Although 440
genetic loci are implicated in type 1 diabetes susceptibility, genes
encoding the human leukocyte antigens (HLA) are the strongest
genetic contributors.1 Killer cell immunoglobulin-like receptors
(KIR) are found on the surface and regulate the function of Natural
Killer (NK) cells, CD8+ and CD4+ αβ T cells as well as γδ T cells.2
Inhibitory KIR (KIR2DL and KIR3DL groups) have immunoreceptor
tyrosine-based motifs within their long cytoplasmic tail. Activating
KIR (KIR2DS and KIR3DS groups) have shorter cytoplasmic tails that
are coupled via a charged residue in the transmembrane region to
adaptor proteins, such as DAP12, which contain immunoreceptor
tyrosine-based activating motifs. Ligands for KIR include class I
HLA. HLA class I alleles are associated with type 1 diabetes, thus
providing a biological rationale to investigate KIR association with
type 1 diabetes.3 KIR haplotypes fall into two types: ‘A,’ containing
mostly inhibitory genes; and ‘B,’ containing one or more activating
KIR genes. Common haplotypes include centromeric (cen) and
telomeric (tel) KIR gene groups, exhibiting strong linkage
disequilibrium within, but not between, groups (Figure 1). The
telomeric A (tA) group includes KIR2DS4, which is the only
potentially short-tailed activating KIR on the A haplotype.
However, KIR2DS4 is disabled by a 22 bp frameshift deletion in
exon 5 on the majority of Caucasian A haplotypes. This distinction
deﬁnes tA01 (KIR2DS4 full length) and tA02 (KIR2DS4 deletion
variant). A small number of studies have reported KIR association
with type 1 diabetes; however, most are small case–control studies
that focus on individual KIR genes and test only the presence or
absence of KIR loci.4 A recent, larger study reports a method for
imputation of KIR copy number for one KIR locus using GWAS SNP
data but reports no signiﬁcant type 1 diabetes association.5 In the
current study, we performed KIR genotyping, with copy number
determination, on a set of type 1 diabetes multiplex families that
we previously genotyped for HLA class I and class II loci.6 This
unique combination of family-based data with complete HLA and
KIR copy number genotyping allows inference of individual
haplotypes, based on identity by descent, for both KIR and HLA.
We tested association of KIR haplotypes with type 1 diabetes in
samples where full HLA context was known. Further, we
tested those patients not carrying the highest-risk HLA genotype,
that is, heterozygotes for DRB1*03:01-DQA1*05:01-DQB1*02:01 and
DRB1*04:01/02/04/05/08-DQA1*03:01-DQB1*03:02 (referred to as
‘DR3/DR4’) separately from the patients who do carry the high-risk
genotype. Finally, given that HLA is associated with age of onset
for type 1 diabetes,7 we examined the KIR genotyping data for
association with age of disease onset.
RESULTS
All families in the Human Biological Data Interchange (HBDI) data
set were complete, with two parents and at least two affected
siblings. All individuals were genotyped for KIR presence or
absence and copy number for each locus.8 All samples were
previously genotyped for the loci HLA-DRB1, -DQA1, -DQB1, -DPB1,
−A, − B and –C and exhibited Mendelian inheritance. Both HLA
and KIR haplotypes were inferred using identity by descent.
Common KIR haplotypes are illustrated schematically in Figure 1.
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Full haplotypes, containing both centromeric and telomeric
portions, showed marginally signiﬁcant overtransmission of KIR
A1 haplotypes to affected individuals (P= 0.0494). Separate
analysis of centromeric and telomeric components of the KIR A1
haplotype (cA01 and tA01) revealed overtransmission of both to
affected individuals, although neither result reached statistical
signiﬁcance. T1D patients were grouped into those who carry
the very high-risk HLA class II genotype known as ‘DR3/4’
(DRB1*03:01-DQA1*05:01-DQB1*02:01 and DRB1*04:01/02/04/05/
08-DQA1*03:01-DQB1*03:02/04 or *02:01) and those who do not
(‘non-3/4’). Transmission Disequilibrium Test (TDT) analyses
revealed no signiﬁcant transmission distortion in the high-risk
DR3/4 group for any KIR haplotype tested. However, KIR A1-
positive association with T1D was observed in the non-3/4 group,
in which the HLA class II attributable risk is lower (P= 0.0096,
Table 1). Analysis of the data with Unphased 3.1.6 software also
revealed this association (P= 0.006, not shown). Separate analysis
of telomeric and centromeric haplotypes showed signiﬁcant
overtransmission of the tA01 (P= 0.0169, Table 1; Unphased:
P= 0.003, not shown). tA01 is included in ~ 55% of common KIR
haplotypes in European populations (Figure 1). To test the
hypothesis that KIR3DL1 may contribute to the T1D predisposing
effect observed for tA01, the data were stratiﬁed by the presence
or absence of HLA-Bw4, the ligand for KIR3DL1. Both the Bw4-
positive and Bw4-negative subsets had overtransmission of tA01
(54.5% and 55.2%, odds ratio = 1.23 and 1.20, respectively), with
the Bw4-negative result reaching the threshold for statistical
signiﬁcance (P= 0.05; data not shown). The fact that tA01
overtransmission is observed either in the presence or absence
of the ligand for KIR3DL1 suggests that the KIR3DL1-Bw4
interaction is not the basis for the disease association of the
tA01 haplotype.
HLA-C alleles can be divided into two groups, C1 and C2,
depending on the identity of the amino-acid residues at position
77 and 80. HLA C2 alleles, which are ligands for 2DS1 and 2DL1, are
underrepresented in T1D, whereas C1 alleles, which are ligands for
2DL2, 2DL3 and 2DS2 (weak interaction), are overrepresented.4
Data from the current study were consistent with that report;
C2 was undertransmitted (frequency transmitted = 0.291, fre-
quency not transmitted = 0.336) to affected individuals, whereas
C1 was overtransmitted (f-trans 0.709, f-not trans = 0.66;
P= 0.000139) (data not shown). However, testing for gene–gene
interaction between HLA-C allele groups and KIR loci showed no
evidence of interaction for any KIR locus with C1 or C2 (data not
shown).
HLA genes, particularly class I, are associated with age of onset
for T1D, suggesting that KIR loci may also be associated in this
manner. Mean age of onset for T1D patients was 11.22 years
(range 0–36 years, s.d. = 7.57; 95%CI = 10.66–11.79); median age of
onset was 10 years. Patients were grouped into four age of onset
categories: (1) 40 and ⩽ 5 (n= 181); (2) 45 and o10 (n= 156);
(3) ⩾ 10 and ⩽ 14 (n= 197), (4) 414 (n= 167). Analysis of patients
in the top age of onset quartile (414 years) revealed signiﬁcant
transmission distortion for several KIR haplotypes, including A2
(63.4%, p [TDT] = 0.024; p[Unphased] = 0.044) and B (41.1%,
p [TDT] = 0.0052; p[Unphased] = 0.001), Table 2). No signiﬁcant
over- or undertransmission of KIR A and B haplotypes was
observed in patients with age of onset 14 or younger. Notably, the
KIR haplotypes that are associated in the over 14 age group
(A2 and B, Table 2) differ from those that are associated in the
non-DR3/4 group (A1, and more speciﬁcally, tA01, Table 1),
although all data were consistent with overtransmission of KIR A
haplotypes and undertransmission of KIR B haplotypes.
DISCUSSION
The fact that some HLA class I molecules are ligands for KIR leads
to the notion that KIR may have a role in T1D susceptibility.
Published reports of KIR association studies with T1D have little
consistency among ﬁndings for particular loci (see allelefrequen-
cies.net/diseases4 and references therein). Most are small case–
control studies based only on presence or absence of individual
KIR loci. The results reported in the current study are based on KIR
haplotypes, inferred using identity by descent from family-based
data, rather than on individual loci.
Our ﬁnding that the predisposing effect of the tA01 haplotype is
more pronounced in the subset of T1D patients not carrying the
high-risk DR3/DR4 genotype increases our conﬁdence that the
observed predisposing effect is real. This is consistent with
previous studies of T1D risk loci other than HLA-DR- and
DQ-encoding genes, including TCF7, IL-4 R and PTPN22, where
Figure 1. Schematic representation of common KIR haplotypes, with the predisposing tA01 gene group boxed in red. The gene content of
tA01 and tA02 are the same, except that tA01 carries the 22 bp frameshift deletion form of KIR2DS4 (2DS4v; 2DS4*003, *004, *006, *007, *008,
*009,* 010, *012, *013), whereas tA02 encodes the full-length gene (2DS4f ). Figure adapted from Jiang et al.8
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the effect of the risk allele was stronger in the non-DR3/4 patients
than in the DR3/4 group.
One report of functional studies in the NOD mouse model of
T1D suggests that expression of the inhibitory receptor KIR3DL1
predisposes NOD mice to diabetes by downregulating function of
regulatory T cells.9 KIR3DL1 is found on telomeric KIR A haplotypes;
thus, our ﬁnding that tA01 haplotypes are predisposing for T1D is
consistent with the NOD result. If the dominance of the inhibitory
or educative activity of KIR3DL1 is important then presumably this
should only be apparent when an appropriate HLA ligand (Bw4+)
is also present. Although no statistically signiﬁcant transmission
distortion was observed in the HBDI data set for KIR in the context
of HLA class I ligands, the combination of KIR3DL1 with the gene
for Bw4-80I (Bw4 molecules that have isoleucine at dimorphic
position 80, which show stronger interaction with KIR3DL1
receptors than Bw4 molecules that have threonine this position
(Bw4-80 T)10,11) exhibited the highest transmission percentage at
54.7% (odds ratio = 1.21, 95% CI 0.92–1.59). Using a combination
of KIR copy number typing and SNP imputation of KIR copy
number, Pontikos et al.5 report no association of 3DL1/3DS1 with
T1D in a large case–control study; however, cases were not
stratiﬁed by HLA, and age of onset for all subjects was less than
17. Although no ﬁrm conclusion about the risk effect of KIR3DL1
on T1D can be made, the combination of evidence from genetic
and animal models warrants further study of this locus. An
alternative explanation for the tA01 association could relate to the
presence of the KIR2DS4v gene that encodes a soluble and
potentially secreted form of the protein. This may be biologically
relevant if it antagonizes the effects of other KIRs.12
These haplotype-based data suggest that KIR genes have a role
in T1D susceptibility. This study was powered with the assumption
that KIR haplotype effects might be similar in magnitude to those
of class I HLA; however, the effect of KIR diversity on T1D
susceptibility appears to be modest. This does not rule out the
possibility that individual KIR loci or haplotypes may have a
substantial effect in a subset of patients. The data point to a role
for KIR in type 1 diabetes risk in older onset patients, which has
been missed in other studies. The fact that the A2 haplotype is
more strongly associated with older age of onset than is the A1
haplotype suggests that the cell-surface receptor KIR2DS4 may
have a role. However, in these data, patients who have at least one
copy of KIR2DS4 appear equally likely to have at least one ligand
for that receptor (C*01:02, *02:02, *04:01, *05:01, *14:02 or *16:01)
in the ⩽ 14 age of onset group compared with the 414 age of
onset group (32% vs 33%, data not shown). A larger data set is
needed to test each ligand independently. The data from this
Table 1. TDT analysis of full, centromeric and telomeric KIR haplotypes for type 1 diabetes association with stratiﬁcation by DR3/4 status
KIR Haplotypea Trans N-trans TDTtestb P-valuec Trans % OR (95% CI)
A B full, non-DR3/4
A1 236 183 6.70 0.0096 56.3% 1.29 (1.06–1.56)
A2 91 91 0.00 1.00 50.0% 1.00 (0.75–1.34)
B 283 314 1.61 0.20 47.4% 0.90 (0.77–1.06)
Others 37 59 5.04 0.0247 38.5% 0.63 (0.42–0.95)
A B full, DR3/4
A1 128 121 0.20 0.66 51.4% 1.06 (0.83–1.36)
A2 53 53 0.00 1.00 50.0% 1.00 (0.68–1.46)
B 185 198 0.44 0.51 48.3% 0.93 (0.76–1.14)
Others 31 25 0.64 0.42 55.4% 1.24 (0.73–2.10)
Cen haplotypes, non-DR3/4
cA01 421 381 2.00 0.16 52.5% 1.10 (0.96–1.27)
cB01 109 117 0.28 0.59 48.2% 0.93 (0.72–1.21)
cB02 80 90 0.59 0.44 47.1% 0.89 (0.66–1.20)
Others 37 59 5.04 0.0247 38.5% 0.63 (0.42–0.95)
Cen haplotypes, DR3/4
cA01 232 220 0.32 0.57 51.3% 1.05 (0.88–1.27)
cB01 67 87 2.60 0.11 43.5% 0.77 (0.56–1.06)
cB02 67 65 0.03 0.86 50.8% 1.03 (0.73–1.45)
Others 31 25 0.64 0.42 55.4% 1.24 (0.73–2.10)
Tel haplotypes, non-DR3/4
tA01 324 266 5.70 0.0169 54.9% 1.22 (1.04–1.43)
tA02 142 149 0.17 0.68 48.8% 0.95 (0.76–1.20)
tB01 144 173 2.65 0.10 45.4% 0.83 (0.67–1.04)
Others 37 59 5.04 0.0247 38.5% 0.63 (0.42–0.95)
Tel haplotypes, DR3/4
tA01 181 189 0.17 0.68 48.9% 0.96 (0.78–1.17)
tA02 93 98 0.13 0.72 48.7% 0.95 (0.71–1.26)
tB01 92 85 0.28 0.60 52.0% 1.08 (0.81–1.45)
Others 31 25 0.64 0.42 55.4% 1.24 (0.73–2.10)
Abbreviations: CI, conﬁdence interval; OR, odds ratio. aA B Full= haplotypes containing both the centromeric and telomeric groups. A1= 3DL3-2DL3-2DP1-
2DL1-3DP1-2DL4-3DL1-2DS4Del-3DL2; A2= 3DL3-2DL3-2DP1-2DL1-3DP1-2DL4-3DL1-2DS4FL-3DL2; B= haplotypes with at least one activating KIR gene;
cA01= 3DL3-2DL3-2DP1-2DL1-3DP1; cB01= 3DL3-2DS2-2DL2-3DP1; cB02= 3DL3-2DS2-2DL2-2DL5C-2DS3S5C-2DP1-2DL1-3DP1; tA01= 2DL4-3DL1-2DS4Del-
3DL2; tA02= 2DL4-3DL1-2DS4FL-3DL2; tB01: 2DL4-3DS1-2DL5-2DS3S5T-2DS1-3DL2; others: haplotypes with frequency o1.0%. bTDT tests were performed
separately for each affected sibling in a family. Testing using an average of the two siblings for each family gave similar results; however, the P-values did not
reach statistical signiﬁcance. cSigniﬁcant P-values (4 0.05) are indicated with bold type. P-values are uncorrected based on prior hypothesis for KIR-T1D
association. Trans, number of transmitted haplotypes; N-trans, number of untransmitted haplotypes.
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report support the notion that KIR A haplotypes, which contain
mostly inhibitory KIR genes, are predisposing for T1D, whereas KIR
B haplotypes, which contain more activating KIR loci, are
protective. Activating KIR could act by stimulating regulatory
T cells to control disease, or by inﬂuencing NK killing of effector
T cells. On the other hand, inhibitory KIR could constrain the
action of T1D-speciﬁc regulatory T cells, or fail to control cytotoxic
T cells, allowing disease progression. In contrast with autoimmune
diabetes in children, where HLA predominates, the genetics of
autoimmune diabetes in adults are not well understood, despite
its relatively high prevalence. Our ﬁnding will potentially be useful
to better categorize patients in the future and to probe the
inﬂuence of KIR on NK/T cells and autoantigen-speciﬁc regulatory
T cells. Given the complexity of both the HLA and KIR genetic loci,
and extreme variability of both among populations, a thorough
understanding of the role of KIR genes and haplotypes in T1D will
require very large sample sets, where individual subsets are large
enough to uncover potential highly signiﬁcant results.
SUBJECTS AND METHODS
The HBDI is a repository for families including children with T1D (National
Disease Research Interchange; http://ndriresource.org/Donor-Programs/
Family-Genetics-HBDI/36/). These families were previously genotyped for
the loci HLA-DRB1, -DQA1, -DQB1, -DPB1, -A, -B and –C and were analyzed
extensively for T1D association.6,13 The 339 families in this study are
multiplex, that is, include more than one affected child. Parents are
unaffected. All families exhibit Mendelian inheritance. HBDI families were
genotyped for HLA class I and class II at two-ﬁeld (four digit) resolution by
polymerase chain reaction sequence-speciﬁc oligonucleotide probe (PCR-
SSO) technology as previously described.6,13 KIR genotype and copy
number were measured using a quantitative PCR comparative Ct method
developed from a protocol for determining genomic copy number as
described earlier.8 Reactions were carried out in quadruplicate to ensure
accuracy of the copy number scoring. Identity by descent-inferred KIR
haplotypes were determined using the Merlin program as previously
described.8 A TDT was applied to the data (two-sided test). Each family was
analyzed as trios for each affected sibling. Odds ratios and 95% conﬁdence
intervals were estimated using the proportion T of transmitted risk allele as
described.14 The estimate of the odds ratio is given by: T/(1− T). In
addition, Unphased software 3.1.615 was used to perform the association
analyses using the allelemain model, which is robust to the issue of the
non-independence of individuals in a sibling pair. The gxg model of the
Unphased software was used to test gene–gene interaction between HLA
allele groups and KIR loci. P-values are uncorrected based on prior
hypothesis for KIR-T1D association.
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Table 2. TDT analysis of full, centromeric and telomeric KIR haplotypes for type 1 diabetes association with stratiﬁcation by age of onset
KIR Haplotypea Trans N-trans TDTtestb P-valuec Trans % OR (95% CI)
A B full, age onset⩽ 14
A1 265 228 2.78 0.10 53.8% 1.16 (0.97–1.39)
A2 96 117 2.07 0.15 45.1% 0.82 (0.63–1.07)
B 362 361 0.00 0.97 50.1% 1.00 (0.87–1.16)
Others 45 62 2.70 0.10 42.1% 0.73 (0.49–1.07)
A B full, age onset 414
A1 95 70 3.79 0.0516 57.6% 1.36 (1.00–1.85)
A2 45 26 5.08 0.0241 63.4% 1.73 (1.07–2.80)
B 102 146 7.81 0.0052 41.1% 0.70 (0.54–0.90)
Others 20 20 0.00 1.00 50.0% 1.00 (0.54–1.86)
Cen haplotypes, age onset ⩽ 14
cA01 472 453 0.39 0.53 51.0% 1.04 (0.92–1.19)
cB01 139 147 0.22 0.64 48.6% 0.95 (0.75–1.19)
cB02 112 106 0.17 0.68 51.4% 1.06 (0.81–1.38)
Others 45 62 2.70 0.10 42.1% 0.73 (0.49–1.07)
Cen haplotypes, age onset 414
cA01 173 140 3.48 0.0621 55.3% 1.24 (0.99–1.54)
cB01 37 56 3.88 0.0488 39.8% 0.66 (0.44–1.00)
cB02 32 46 2.51 0.11 41.0% 0.70 (0.44–1.09)
Others 20 20 1.00 1.00 50.0% 1.00 (0.54–1.86)
Tel haplotypes, age onset ⩽ 14
tA01 375 333 2.49 0.11 53.0% 1.13 (0.97–1.31)
tA02 166 191 1.75 0.19 46.5% 0.87 (0.71–1.07)
tB01 182 182 0.00 1.00 50.0% 1.00 (0.81–1.23)
Others 45 62 2.70 0.10 42.1% 0.73 (0.49–1.07)
Tel haplotypes, age onset 414
tA01 123 112 0.51 0.47 52.3% 1.10 (0.85–1.42)
tA02 66 55 1.00 0.32 54.5% 1.20 (0.84–1.72)
tB01 53 75 3.78 0.0518 41.4% 0.71 (0.50–1.00)
Others 20 20 0.00 1.00 50.0% 1.00 (0.54–1.86)
aA B Full= haplotypes containing both the centromeric and telomeric groups. A1= 3DL3-2DL3-2DP1-2DL1-3DP1-2DL4-3DL1-2DS4Del-3DL2; A2= 3DL3-2DL3-
2DP1-2DL1-3DP1-2DL4-3DL1-2DS4FL-3DL2; B=haplotypes with at least one activating KIR gene; cA01= 3DL3-2DL3-2DP1-2DL1-3DP1; cB01= 3DL3-2DS2-
2DL2-3DP1; cB02= 3DL3-2DS2-2DL2-2DL5C-2DS3S5C-2DP1-2DL1-3DP1; tA01= 2DL4-3DL1-2DS4Del-3DL2; tA02= 2DL4-3DL1-2DS4FL-3DL2; tB01:
2DL4-3DS1-2DL5-2DS3S5T-2DS1-3DL2; Others: haplotypes with frequency o1.0%. bTDT tests were performed separately for each affected sibling in a
family. Testing using an average of the two siblings for each family gave similar results; however, the P-values did not reach statistical signiﬁcance. cSigniﬁcant
P-values (40.05) are indicated with bold type. P-values are uncorrected based on prior hypothesis for KIR-T1D association. Trans, number of transmitted
haplotypes; N-trans, number of untransmitted haplotypes.
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